Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19504
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStefanou, D. G.en
dc.contributor.authorNonni, A. V.en
dc.contributor.authorAgnantis, N. J.en
dc.contributor.authorAthanassiadou, S.en
dc.contributor.authorBriassoulis, E.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T19:00:18Z-
dc.date.available2015-11-24T19:00:18Z-
dc.identifier.issn0250-7005-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19504-
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBone Neoplasms/*classification/mortality/*pathology/therapyen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Proteins/analysisen
dc.subject*Nuclear Proteinsen
dc.subjectProto-Oncogene Proteins/*analysis/geneticsen
dc.subjectProto-Oncogene Proteins c-mdm2en
dc.subjectRetrospective Studiesen
dc.subjectSarcoma/*classification/mortality/*pathology/therapyen
dc.subjectSurvival Analysisen
dc.subjectTime Factorsen
dc.subjectTumor Suppressor Protein p53/*analysis/geneticsen
dc.titlep53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9891539-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1998-
heal.abstractThe aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. We selected 40 cases of human sarcomas comprising 6 malignant fibrous histiocytomas (MFH), 1 fibrosarcoma, 1 dermatofibrosarcoma protuberans, 5 liposarcomas, 9 leiomyosarcomas, 1 rhabdomyosarcoma, 3 synovial sarcomas, 2 osteosarcomas, 1 chondrosarcoma, 4 Ewing's sarcomas, 2 Kaposi's sarcomas, 1 malignant haemangiopericytoma, 1 phylloides cystosarcoma, 1 neuroblastoma, 1 chordoma and 1 unclassified sarcoma. All the immunohistochemical markers, which had been used for the characterization of these sarcomas were re-examined. Additionally, the Streptavidin-Biotin peroxidase method was performed on paraffin sections using the monoclonal antibodies: anti-p53 antibody DO7, anti-MDM-2 antibody IF2 and anti-Ki-67 antibody MIB-1. According to our results, p53 protein nuclear expression was detected in 20% (8/40) of the tumours (1 fibrosarcoma, 2 liposarcomas, 1 leiomyosarcoma, 1 rhabdomyosarcoma, 2 Ewing's sarcomas and 1 unclassified sarcoma). MDM-2 nuclear staining was determined in 7.5% (3/40) of the cases (1 MFH and 2 liposarcomas). A high proliferative index was demonstrated in 27.5% (11/40) of the tumours (2 MFH, 4 leiomyosarcomas, 1 rhabdomyosarcoma, 1 osteosarcoma, 2 Ewing's sarcomas and 1 unclassified sarcoma). p53 overexpression was associated with high tumour grade (p < 0.05) and MIB-1 expression was correlated with reduced survival (p < 0.05), but p53 overexpression was not significantly associated with either MIB-1 score or with overall survival of the patients. In conclusion, from this limited and heterogeneous sample of cases, we suggest that the p53/MDM-2 pathway is involved in the tumourigenesis of several sarcoma subtypes, but it is unclear if the overexpression of these genes may become prognostic marker for patients affected with these highly aggressive tumours.en
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons